Retinal function abnormalities in patients treated with vigabatrin

Archives of Ophthalmology

Volumn 121, Issue 6, 2003, Pages 811-816

  Banin, Eyal ^a   Shalev, Ruth S ^b   Obolensky, Alexey ^a   Neis, Ruhama ^a   Chowers, Itay ^a   Gross Tsur, Varda ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FELBAMATE; LAMOTRIGINE; PHENYTOIN; VALPROIC ACID; VIGABATRIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COLOR VISION TEST; ELECTRORETINOGRAPHY; EPILEPSY; HUMAN; MALE; NERVE FUNCTION; OPHTHALMOSCOPY; PERIMETRY; PRIORITY JOURNAL; RETINA DISEASE; RETINA FOVEA; RETINA ROD; VISUAL FIELD;

ADOLESCENT; ADULT; ANTICONVULSANTS; COLOR PERCEPTION TESTS; DARK ADAPTATION; ELECTRORETINOGRAPHY; EPILEPSY; HUMANS; MALE; MIDDLE AGED; PERIMETRY; PHOTORECEPTORS, VERTEBRATE; RETINAL DISEASES; VIGABATRIN; VISION DISORDERS; VISUAL FIELDS;

EID: 0037672875     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.121.6.811     Document Type: Article

References (35)

1. Ben-Mehachem E. Vigabatrin. Epilepsia. 1995;36(suppl 2):S95-S104.
2. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systemic review of their efficacy and tolerability. Epilepsia. 1997;38:859-880.
3. Chiron C, Dulac O, Luna L, et al. Vigabatrin in infantile spasms. Lancet. 1990; 335:363-364.
4. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol. 1999;14:71-74.
5. Meldrum BS. GABAergic mechanisms in the pathogenesis and treatment of epilepsy. Br J Clin Pharmacol. 1989;27:3S-11S.
6. Tanganelli P, Regesta G. Vigabatrin vs carbamazepine monotherapy in newly diagnosed focal epilepsy: a randomized response conditional crossover study. Epilepsy Res. 1996;25:257-262.
7. Elke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ. 1997;314:180-181.
8. Wild JM, Martinez C, Reinshagen G, Harding GF. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia. 1999;40:1784-1794.
9. Kalviainen R, Nousiainen I, Mantyjarvi M, et al. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology. 1999;53:922-966.
10. Miller NR, Johnson MA, Paul SR, et al. Visual dysfunction in patients receiving vigabatrin. Neurology. 1999;53:922-926.
11. Daneshvar H, Racette L, Coupland SG, et al. Symptomatic and asymptomatic visual loss in patients taking vigabatrfn. Ophthalmology. 1999;106:1792-1798.
12. Harding GFA, Wild JM, Robertson KA, et al. Separating the retinal electrophysiologic effects of vigabatrin: treatment versus field loss. Neurology. 2000;55:347-352.
13. Gross-Tsur V, Banin E, Shahar E, et al. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol. 2000;48:60-64.
14. Johnson MA, Krauss GL, Miller NR, et al. Visual function loss from vigabatrin: effect of stopping the drug. Neurology. 2000;55:40-45.
15. Nousiainen I, Kalvainen R, Mantyjarvi M. Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy. Ophthalmology. 2000;107:884-888.
16. Hilton EJ, Cubbidge RP, Hosking SL, Betts T, Comaish IF. Patients treated with vigabatrin exhibit central visual function loss. Epilepsia. 2002;43:1351-1359.
17. Coupland SG, Zackon DH, Leonard BC, Ross TM. Vigabatrin effect on inner retinal function. Ophthalmology. 2001;108:1493-1496.
18. Besch D, Kurtenbach A, Apfelstedt-Sylia E, et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Ooc Ophthalmol. 2002;104: 151-170.
19. Jensen H, Sjo O, Uldall P, Gram L. Vigabatrin and retinal changes. Doc Ophthal-mol. 2002;104:171-180.
20. van der Torren K, Graniewski-Wijnands HS, Polak BCP. Visual field and electrophysiological abnormalities due to vigabatrin. Doc Ophthalmol. 2002;104:181-188.
21. Comaish IF, Gorman C, Brimlow GM, Barber C, Orr GM, Galloway NR. The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms. Doc Ophthalmol. 2002; 104:195-212.
22. Jacobson SG, Voigt WJ, Parel J-M, et al. Automated light- and dark-adapted perimetry for evaluating retinitis pigmentosa. Ophthalmology. 1986;93:1604-1611.
23. Arndt CF, Derambure P, Defoort-Dehellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology. 1999;52:1201-1205.
24. Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67:716-722.
25. Ruether K, Pung T, Kellner U, et al. Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin. Arch Ophthalmol. 1998;116:817-818.
26. Ponjavic V, Anreasson S. Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication. Doc Ophthatmol. 2001;102:63-72.
27. Harding GFA, Wild JM, Robertson KA, et al. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction. Epilepsia. 2000;41:1420-1431.
28. Westall CA, Logan WJ, Smith K, Buncic JR, Panton CM, Abdolell M. The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin. Doc Ophthatmol. 2002;104:133-149.
29. C receptors to rod and cone bipolar cells in a rat retinal slice preparation. J Neurophysiol. 1998;79: 1384-1395.
30. Masland RH. Amacrine cells. Trends Neurosci. 1988;11:405-410.
31. Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague-Dawley and Lister-Hooded rats. Toxicol Pathol. 1987;15:143-148.
32. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology. 1998; 50:614-618.
33. Grover S. In discussion of Coupland SG, Zackon DH, Leonard BC, Ross TM. Vigabatrin effect on inner retinal function. Ophthalmology. 2001;108:1497-1498.
34. Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H. Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry. 2001;70:787-789.
35. Hardus P, Verduin WM, Postma G, et al. Long-term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol. 2000; 84:788-790.